STOPKIN, led by Catherine Guillou, Director of Research at the Institut de Chimie des Substances Naturelles (CNRS/Université Paris-Saclay) and Anne Houdusse, Director of Research at the Institut Curie, offers a new therapeutic approach to the fight against cancer. STOPKIN is developing small molecules targeting a kinesin overexpressed in many cancers, and in cancer cells that have become resistant to radiation or chemotherapy.
RISE : une 9ème promotion de projets de start-up soutenus par le CNRS